Does participation in psychosocial treatment augment the benefit of clozapine?

Archives of General Psychiatry

Volumn 55, Issue 7, 1998, Pages 618-625

  Rosenheck, Robert ^a,b,f   Tekell, Janet ^c   Peters, Jeffrey ^d   Cramer, Joyce ^a,b   Fontana, Alan ^a,b   Xu, Weichun ^e   Thomas, Jonathan ^e   Henderson, William ^e   Charney, Dennis ^a,b  

^a West Haven   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e Mines Vet Affairs Medical Center   (United States)

^f Veterans Affairs Connecticut Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CASE MANAGEMENT; CLOZAPINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HOSPITALIZATION; HOSPITALS, VETERANS; HUMANS; MALE; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT PARTICIPATION; PSYCHOTHERAPY; QUALITY OF LIFE; REHABILITATION, VOCATIONAL; SCHIZOPHRENIA; SOCIAL SUPPORT;

EID: 0031855311     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.55.7.618     Document Type: Article

References (35)

1. Davis JM, Barter JT, Kane JM. Antipsychotic drugs. In: HI Kaplan, Sadock BJ, eds. Comprehensive Textbook of Psychiatry. Vol 5. Baltimore, Md: Williams & Wilkins; 1989:1591-1626.
2. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull. 1993;19:287-302.
3. Kane JM, Honigfeld G, Singer J, Meltzer HY, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
4. Brier A, Buchanan RW, Kirkpatrick B. Clozapine in schizophrenic outpatients: effects on positive and negative symptoms. Am J Psychiatry. 1994;151:20-26.
5. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM. Clinical effects of Clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry. 1994;151:1744-1752.
6. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull. 1996;32:683-697.
7. Rosenheck RA, Cramer J, Xu W, Thomas J, Henderson W, Frisman LK, Fye C, Charney D, for the Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. A comparison of Clozapine and naloperidol in the treatment of hospitalized patients with refractory schizophrenia. N Engl J Med. 1997;337:809-815.
8. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull. 1995;21:579-591.
9. Carpenter WT, Conley RR, Buchanan RW, Breier A, Tamminga C. Patient response and resource management: another view of Clozapine treatment of schizophrenia. Am J Psychiatry. 1996;152:827-832.
10. Meltzer HY, Clozapine: is another view valid? Am J Psychiatry. 1996;152:821-825.
11. Brier A, Buchanan RW, Irish D, Carpenter WT. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry. 1993;44:1145-1149.
12. Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry. 1990;41:892-897.
13. Marder SR. Adverse effects of clozapine. J Clin Psychiatry. 1996;14(suppl 2): 11-12.
14. Massachusetts mental health advocates cite problems in Medicaid managed care program [News and Notes]. Psychiatric Serv, 1997;48:1215.
15. Hogarty GE, Goldberg SO, Schooier NR, Ulrich RF, and the Collaborative Study Group. Drug and sociotherapy in the aftercare of schizophrenic patients, II: two-year relapse rates. Arch Gen Psychiatry. 1974;31:603-608.
16. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry. 1979;36:1283-1294.
17. Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Javna CD, Madonia MJ. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia, I: one-year effects of a controlled study on relapse and expressed emotion. Arch Gen Psychiatry. 1986;43:633-642.
18. Schooler NR, Keith SJ, Severe JB, Matthews SM. Maintenance treatment of schizophrenia: a review of dose reduction and family management strategies. Psychiatr Q. 1995;66:279-292.
19. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A, Jacobs M, Lieberman JA, Mance R, Simpson GM, Woerner MG. Relapse and rehospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Arch Gen Psychiatry. 1997;54:453-463.
20. Spitzer RS, Endicott JE. The Semi-structured Clinical Interview for Diagnosis. Washington, DC: American Psychiatric Press; 1990.
21. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
22. Guy W. Clinical global impression. In: Guy W, ed. ECDEU Assessment Manual for Psyche-pharmacology. Rockville, Md: National Institute of Mental Health; 1976. Dept of Health Education and Welfare publication ADM 76-338.
23. Stein LI, Test MA, Alternative to mental hospital treatment, I: conceptual model, i treatment program, and clinical evaluation. Arch Gen Psychiatry. 1980;37:392-397.
24. Kay SR, Fishbein G, Opler DR. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
25. Heinrichs DW, Hanlon ET, Carpenter WT. The Quality-Of-Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10: 388-398.
26. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;131:222-223.
27. Guy W. Abnormal involuntary movements. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology.Rockville, Md: National Institute of Mental Health; 1976. Dept of Health Education and Welfare publication AD M 76-338.
28. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;11-19.
29. Hayduk LA. Structural Equation Modeling With Lisrel. Baltimore, Md: The Johns Hopkins University Press; 1987.
30. SAS Institute Inc. SAS/STAT Software: CALIS and LOGISTIC Procedures. Gary, NC: SAS Institute; 1990. SAS Technical Report P-200.
31. Rossi PH, Freeman HE. Evaluation: Systematic Approach. Newbury Park, Calif: Sage Publications; 1989.
32. Salive ME, Mayfield JA, Weissman NW. Patient outcomes research teams and the Agency for Health Care Policy Research. Health Serv Res. 1990;25:697-708.
33. Detsky AS, Evidence of effectiveness. In: Sloan FA, ed. Valuing Health Care. New York, NY: Cambridge University Press; 1996.
34. Carrol K, Kadden RM, Donovan DM, Zweben A, Rounseville B. Implementing treatments: protecting the validity of the independent variable in treatment matching studies. J Stud Alcohol. 1994; (suppi 12):149-155.
35. Hogarty GE, Schooler MR, Baker RW. Efficacy versus effectiveness. Psychiatr Serv. 1997;48:1107.